Nvidia’s results, Indian tariffs, French markets - what’s moving markets
Following this sale, Radovich still holds 26,961 shares in Mirum Pharmaceuticals (NASDAQ:MIRM). The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. According to InvestingPro, the company maintains a healthy financial position with a current ratio of 3.34, indicating strong liquidity. Analysts maintain a Strong Buy consensus on the stock, with detailed analysis and additional insights available in the comprehensive Pro Research Report. According to InvestingPro, the company maintains a healthy financial position with a current ratio of 3.34, indicating strong liquidity. Analysts maintain a Strong Buy consensus on the stock, with detailed analysis and additional insights available in the comprehensive Pro Research Report.
Following this sale, Radovich still holds 26,961 shares in Mirum Pharmaceuticals. The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing.
In other recent news, Mirum Pharmaceuticals has exceeded its 2024 sales guidance with net product sales of approximately $336 million, while projecting a promising outlook for 2025 with expected global net product sales between $420 million and $435 million. The company’s growth was boosted by the expanded use of its drug LIVMARLI and positive interim results for its volixibat treatments in cholestatic diseases. Additionally, Mirum submitted a New Drug Application for chenodiol and acquired rights to MRM-3379 for Fragile X syndrome, strengthening its rare genetic neurology portfolio.
Mirum’s financial health is marked by a year-end cash balance of roughly $287 million and positive cash flow from operations in the third quarter of 2024. The company anticipates significant advancements in its clinical programs, with the VISTAS study of volixibat expected to complete enrollment in the second half of 2025 and topline data anticipated in 2026. The FDA has set a Prescription Drug User Fee Act date for chenodiol in cerebrotendinous xanthomatosis for March 28, 2025, signifying a potential expansion in the company’s treatment offerings.
Mirum’s global reach has expanded to 30 countries, with successful product launches in major European markets. The company’s executive team was also enhanced with the appointment of Dr. Joanne Quan as Chief Medical (TASE:PMCN) Officer. Lastly, H.C. Wainwright has reaffirmed a Buy rating on Mirum Pharmaceuticals, following the company’s robust third-quarter sales and an upward revision of its full-year sales forecast for 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.